A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
This study assesses the safety, tolerability, and efficacy of suvorexant in multiple
sclerosis patients. Enrolled subjects will receive 2 weeks of treatment during treatment
period 1 with either suvorexant or matching placebo (1:1). After treatment period 1, subjects
will undergo a washout period of 1 week then 2 weeks of the alternate treatment (either
suvorexant or placebo). The primary hypothesis is that suvorexant will provide greater
improvement in sleep, as measured by symptom rating scales, compared to placebo.